Hepatitis/MASH

The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.

Latest News

Hepatocellular Carcinoma Cells: These liver cells, or hepatocytes, can develop into tumors in the liver, often associated with cirrhosis or chronic liver disease - Image credit: Best | stock.adobe.com
FDA Approves Y-90 Resin Microspheres for Unrespectable Hepatocellular Carcinoma

July 7th 2025

Y-90 resin microspheres offer a new option for liver cancer patients for the treatment of unresectable hepatocellular carcinoma.

Hepatitis C virus model, 3D illustration. A virus consists of a protein coat, capsid, surrounding RNA and outer lipoprotein envelope with 2 types of glycoprotein spikes, E1 and E. - Image credit: Dr_Microbe | stock.adobe.com
Glecaprevir/Pibrentasvir Combination Receives FDA Approval Expanded Indication for Acute HCV

June 11th 2025

Hepatocellular carcinoma -- Image credit: sinhyu | stock.adobe.com
Study Finds VPS72 Is Overactive in Patients With Hepatocellular Carcinoma

June 6th 2025

Metabolic dysfunction-associated steatohepatitis (MASH) -- Image credit: Angelov | stock.adobe.com
GLP-1 Receptor Agonists and FGF21 Analogues May Be Key Treatments for MASH-Related Cirrhosis

June 4th 2025

More News